T1	condition 14 45	pegfilgrastim-induced bone pain
T2	total-participants 551 554	510
T3	intervention 594 602	naproxen
T4	control 633 640	placebo
T5	outcome-Measure 859 915	area under the curve (AUC) for pain for days 1 through 5
T6	outcome-Measure 975 1015	risk factors for the development of pain
T7	outcome-Measure 1020 1040	response to naproxen
T8	age 1065 1075	55.6 years
T9	outcome 1172 1176	Pain
T10	outcome 1225 1242	mean AUC for pain
T11	outcome 1335 1347	maximum pain
T12	outcome 1400 1422	overall pain incidence
T14	outcome 1506 1530	reduction in severe pain
T13	cv-cont-mean 1247 1251	7.71
T15	iv-cont-mean 1278 1282	6.04
T16	outcome 1458 1466	duration
T17	iv-cont-mean 1472 1476	2.40
T18	iv-cont-mean 1480 1489	1.92 days
T19	iv-cont-mean 1428 1433	71.3%
T20	iv-cont-mean 1437 1442	61.1%
T21	iv-cont-mean 1353 1357	3.40
T22	iv-cont-mean 1361 1365	2.59
T23	iv-cont-mean 1564 1569	27.0%
T24	iv-cont-mean 1573 1578	19.2%
